Welcome to Asmacure!

CORPORATE OVERVIEW

Asmacure Ltée is a clinical-stage biopharmaceutical company focused on the development of novel, proprietary nicotinic receptor modulator compounds for the treatment of inflammatory diseases. The company’s lead compound, ASM-024, was the first nicotinic receptor modulator to enter clinical testing for the treatment of asthma. Asmacure was founded in 2002 and is based in Quebec City, Quebec, Canada.

TECHNOLOGY

Small molecules, novel nicotinic acetylcholine receptor modulator

  • Activity demonstrated in preclinical in vitro, ex vivo and in vivo models of inflammation and/or asthma, including in mice, dogs, and human cells and pulmonary tissue
  • Potential applications in other inflammatory respiratory and non-respiratory diseases

POTENTIAL MARKET AND POSITIONING

  • Respiratory Diseases : 300 million people affected worldwide;
    Market Size ~ $ 30 Billion for respiratory diseases and asthma ~ $15 Billion.
  • Asmacure’s library of novel, proprietary compounds represent a potential new pharmacological mechanism for the treatment of asthma and other respiratory inflammatory diseases.
  • Asmacure’s lead compound exhibits the dual properties expected to translate into anti-inflammatory and bronchodilating effects in a single-entity

DEVELOPMENT STATUS

  • Lead compound - ASM-024 – in clinical development
    • Two Phase I studies completed
    • Two Phase II studies ongoing, one-in patients with mild asthma and one involving patients with moderate asthma
  • Analogues being tested in preclinical models of other inflammatory diseases with high unmet needs in current clinical practice